博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300404 博济医药

已收盘 05-24 15:00:00

{"stockData":{"symbol":"300404","market":"SZ","secType":"STK","nameCN":"博济医药","latestPrice":7.63,"timestamp":1716534216000,"preClose":7.62,"halted":0,"volume":5526340,"delay":0,"floatShares":275000000,"shares":382000000,"eps":0.0762,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"05-24 15:00:00","open":7.65,"high":7.75,"low":7.56,"amount":42237100,"amplitude":0.0249,"askPrice":7.64,"askSize":132,"bidPrice":7.63,"bidSize":49,"shortable":0,"etf":0,"ttmEps":0.0762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716773400000},"adr":0,"adjPreClose":7.62,"symbolType":"stock","openAndCloseTimeList":[[1716514200000,1716521400000],[1716526800000,1716534000000]],"highLimit":8.38,"lowLimit":6.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":382207238,"pbRate":3.04,"roa":"--","roe":"1.72%","epsLYR":0.0657,"committee":0.261951,"marketValue":2916000000,"floatMarketCap":2101000000,"peRate":100.131232,"changeRate":0.0013,"turnoverRate":0.0201,"status":0},"requestUrl":"/m/hq/s/300404","defaultTab":"news","newsList":[{"id":"2436196969","title":"博济医药(300404.SZ)拟10股派0.1元 于5月27日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2436196969","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2436196969?lang=zh_cn&edition=full","pubTime":"2024-05-17 21:05","pubTimestamp":1715951145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)公告，公司2023年年度权益分派拟：向全体股东每10股派发现金分红人民币0.1元(含税)。除权除息日为：2024年5月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122859.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435321180","title":"博济医药：目前公司有为客户提供CAR-T项目的注册、临床前、临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2435321180","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435321180?lang=zh_cn&edition=full","pubTime":"2024-05-13 20:01","pubTimestamp":1715601709,"startTime":"0","endTime":"0","summary":"目前相关项目还在研发过程中，进展顺利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300023695.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434814881","title":"海通国际：给予博济医药增持评级，目标价位11.74元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434814881","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434814881?lang=zh_cn&edition=full","pubTime":"2024-05-11 09:35","pubTimestamp":1715391315,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng近期对博济医药进行研究并发布了研究报告《公司季报点评：首次覆盖：博济医药：2024年一季度业绩恢复高增速，订单快速增长》，本报告对博济医药给出增持评级，认为其目标价位为11.74元，当前股价为8.07元，预期上涨幅度为45.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051100016164.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434291886","title":"博济医药（300404）5月10日主力资金净卖出1839.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434291886","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434291886?lang=zh_cn&edition=full","pubTime":"2024-05-10 15:25","pubTimestamp":1715325944,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月10日收盘，博济医药报收于8.07元，下跌4.5%，换手率5.71%，成交量15.72万手，成交额1.28亿元。5月10日的资金流向数据方面，主力资金净流出1839.54万元，占总成交额14.37%，游资资金净流入1325.86万元，占总成交额10.36%，散户资金净流入513.68万元，占总成交额4.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000023012.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433440828","title":"博济医药：关于AI技术应用于临床试验领域的相关项目目前仍在讨论和探索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2433440828","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433440828?lang=zh_cn&edition=full","pubTime":"2024-05-06 18:06","pubTimestamp":1714989967,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)05月06日在投资者关系平台上答复投资者关心的问题。投资者：中国经济大讲堂]新药研发外包模式创新。人工智能在新药研发是cro企业的唯一出路！请问贵公司，进展？以及推进方式？博济医药董秘：您好，关于AI技术应用于临床试验领域的相关项目目前仍在讨论和探索阶段。感谢您的关注！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600020607.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431857144","title":"博济医药：目前公司有为客户提供双抗ADC药物的临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857144","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431857144?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:01","pubTimestamp":1714395713,"startTime":"0","endTime":"0","summary":"博济医药董秘：您好，公司一季度应收账款上升主要是公司一季度收入增长所致，公司一直重视对应收账款的管理，收款责任及催款程序均有明确的分工和规定，公司持续执行应收账款催收程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900030934.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430727840","title":"博济医药赴珍宝岛药业交流、洽谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2430727840","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2430727840?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:43","pubTimestamp":1714131794,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，据珍宝岛药业消息，4月26日，博济医药科技股份有限公司董事长王廷春一行赴珍宝岛药业交流、洽谈。王廷春谈到，博济医药历经多年科学发展，作为专业从事CRO+CDMO的新型高新技术企业，双方在新药研发、临床研究、药品注册等多领域均具备合作空间。珍宝岛药业近年来产品管线拓展动作频繁，博济医药愿同珍宝岛药业建立更为紧密的合作联系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261943198b570f08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261943198b570f08&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430263384","title":"博济医药（300404）2024年一季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430263384","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430263384?lang=zh_cn&edition=full","pubTime":"2024-04-26 06:22","pubTimestamp":1714083747,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2024年一季报。根据财报显示，本报告期中博济医药营收净利润同比双双增长，应收账款上升。截至本报告期末，公司营业总收入1.67亿元，同比上升62.08%，归母净利润1651.31万元，同比上升40.67%。具体财务指标见下表：证券之星价投圈财报分析工具显示：资产质量方面，公司应收账款体量较大。营收分析方面，公司最新一期年度报表的现金流为正，经营性现金流和利润相匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600013739.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430849132","title":"博济医药：4月25日接受机构调研，开源证券、兴业证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2430849132","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430849132?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:15","pubTimestamp":1714054523,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月25日博济医药发布公告称公司于2024年4月25日接受机构调研，开源证券、兴业证券、中泰证券、中原证券、招商证券、光大证券、国联证券、华创证券、华安证券、海通证券、民生证券、申万宏源证券、太平洋证券参与。目前公司商务团队布局已基本完成，随着公司营收上升，销售费用率会有所下降。博济医药主营业务：为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500046021.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430469039","title":"图解博济医药一季报：第一季度单季净利润同比增40.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430469039","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430469039?lang=zh_cn&edition=full","pubTime":"2024-04-25 01:30","pubTimestamp":1713979847,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药2024年一季报显示，公司主营收入1.67亿元，同比上升62.08%；归母净利润1651.31万元，同比上升40.67%；扣非净利润1449.3万元，同比上升103.3%；负债率32.19%，投资收益56.91万元，财务费用-51.5万元，毛利率33.83%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500002157.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429438126","title":"博济医药最新公告：一季度净利润1651.31万元 同比增长40.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429438126","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429438126?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:01","pubTimestamp":1713952904,"startTime":"0","endTime":"0","summary":"博济医药公布2024年一季度报告，报告期营业收入1.67亿元，同比增长62.08%；归属于上市公司股东的净利润1651.31万元，同比增长40.67%；基本每股收益0.0432元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400037945.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429048202","title":"博济医药(300404.SZ)发布一季度业绩，净利润1651.31万元 同比增加40.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429048202","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429048202?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:20","pubTimestamp":1713950427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布2024年一季度报告，报告期内公司实现营业收入1.67亿元，同比增加62.08%;归属于上市公司股东的净利润1651.31万元，同比增加40.67%;归属于上市公司股东的扣除非经常性损益的净利润1449.3万元，同比增加103.3%;基本每股收益0.0432元.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108557.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429205482","title":"博济医药(300404.SZ)发布2023年度业绩，净利润2433.94万元 同比减少12.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429205482","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429205482?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:15","pubTimestamp":1713950158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布2023年年度业绩报告，报告期内公司实现营业收入5.56亿元，同比增加31.19%;归属于上市公司股东的净利润2433.94万元，同比减少12.04%;归属于上市公司股东的扣除非经常性损益的净利润1001.74万元，同比减少24.24%;基本每股收益0.0657元，公司拟向全体股东每10股派发现金红利0.1元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108552.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413461851","title":"实现意念操控鼠标，脑机接口新突破！马斯克的宏伟抱负不远了","url":"https://stock-news.laohu8.com/highlight/detail?id=2413461851","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2413461851?lang=zh_cn&edition=full","pubTime":"2024-02-21 11:36","pubTimestamp":1708486573,"startTime":"0","endTime":"0","summary":"脑机接口+AI，BUFF加满！","market":"hk","thumbnail":"https://img3.gelonghui.com/3a484-96ddda57-10d3-468f-bdb1-97fa798b111a.jpg?guru_height=638&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3a484-96ddda57-10d3-468f-bdb1-97fa798b111a.jpg?guru_height=638&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/695058","is_publish_highlight":false,"gpt_icon":0},{"id":"2413455933","title":"博济医药签减肥神药订单股价涨20% 临床研究服务业务增长贡献7成营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2413455933","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2413455933?lang=zh_cn&edition=full","pubTime":"2024-02-21 08:06","pubTimestamp":1708473960,"startTime":"0","endTime":"0","summary":"　　博济医药签署龙年首个医药服务合同大单。　　2月19日晚间，博济医药发布公告称，公司就“司美格鲁肽注射液”临床研究服务签订了《技术服务（委托）合同》，合同总金额为1.08亿元。　　或受此消息刺激，该公告发布后次日，即2月20日开盘后，博济医药股价涨停，涨幅20.03%。　　据了解，博济医药为“CRO+CDMO”医药外包企业，临床研究服务近年来快速增长，2023年上半年，这一板块营收占公司总营收比例达74.82%，成为公司营收的绝对支柱。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-02-21/doc-inaitxcu0298385.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-02-21/doc-inaitxcu0298385.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2412909683","title":"博济医药(300404.SZ)与诺泰生物签约 受托提供司美格鲁肽注射液临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2412909683","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2412909683?lang=zh_cn&edition=full","pubTime":"2024-02-19 16:00","pubTimestamp":1708329600,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告，公司与诺泰生物签订了《技术服务(委托)合同》，合同总金额为1.08亿元(含税)。合同约定诺泰生物委托博济医药提供“司美格鲁肽注射液”临床研究服务，即负责监查完成“司美格鲁肽注射液”用于治疗2型糖尿病、肥胖患者的临床疗效和安全性研究。公告称，通过本次合作，将进一步增强公司在内分泌疾病领域的研发能力。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqhcn2087271.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqhcn2087271.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2412778905","title":"博济医药(300404.SZ)子公司化学原料药“他达拉非”上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2412778905","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2412778905?lang=zh_cn&edition=full","pubTime":"2024-02-19 15:52","pubTimestamp":1708329120,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告，公司全资子公司广州博济生物医药科技园有限公司申报的“他达拉非”获得国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》。公告显示，“他达拉非”是环磷酸鸟苷(cGMP)特异性磷酸二酯酶5(PDE5)的选择性、可逆性抑制剂。本品用于治疗男性勃起功能障碍，以及勃起功能障碍合并良性前列腺增生的症状和体征。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqhci2550513.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqhci2550513.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-04-24","address":"广东省广州市黄埔区科学城南翔一路62号(二,三,四,五)栋","stockEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0931},{"period":"3month","weight":-0.0415},{"period":"6month","weight":-0.2316},{"period":"1year","weight":-0.2052},{"period":"ytd","weight":-0.1475}],"companyName":"博济医药科技股份有限公司","boardCode":"AI0073","perCapita":"11392股","boardName":"研究和试验发展","registeredCapital":"38220万元","compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0145},{"period":"3month","weight":0.028},{"period":"6month","weight":0.0158},{"period":"1year","weight":-0.0351},{"period":"ytd","weight":0.0383}],"survey":"　　博济医药科技股份有限公司主要业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司主要服务包括临床研究服务、临床前研究服务、CDMO服务、其他咨询服务、临床前自主研发、技术成果转化服务等。公司在报告期内荣膺“2023中国医药服务最具竞争力企业10强”“2022中国医药CRO企业20强”“2022年度中国医药研发50强”等荣誉称号。","serverTime":1716630383062,"listedPrice":12.87,"stockholders":"24171人(较上一季度增加9.42%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博济医药,300404,博济医药股票,博济医药股票老虎,博济医药股票老虎国际,博济医药行情,博济医药股票行情,博济医药股价,博济医药股市,博济医药股票价格,博济医药股票交易,博济医药股票购买,博济医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}